The firm brings unique experience to tracking, assessing and explaining regulatory and reimbursement policy that affect the biopharmaceutical industry. The company’s goal is to advance mutual understanding among policymakers, business executives and the investment community, in the belief that a deeper understanding of policy leads to better business, and a deeper understanding of business leads to better policy.
Member Sign In:
- Part D More Efficient Than B? OIG Report Says Part B Overpays for Fees for Certain Drugs Compared to Other Programs Sep. 16, 2014
- Clarus Oral Testosterone Therapy Faces Tough Panel Review: Bad Time For “Easier-To-Use” Options Sep. 16, 2014
- FDA/NCI Cancer Signals Meeting Starts Process Towards Post-Approval Guidance; FDA’s Graham Discusses Current Projects Sep. 15, 2014
See More Research Notes